Robust in vivo differentiation of t(8;21)-positive acute myeloid leukemia blasts to neutrophilic granulocytes induced by treatment with dasatinib.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

10 citing papers in PubMed.

1. A phase 3 study of intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.Blood · 2026
   Trial
2. Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trial.Leukemia · 2018
   Trial
3. AML1/ETO and its function as a regulator of gene transcription via epigenetic mechanisms.Oncogene · 2021
   Review
4. Dasatinib overrides the differentiation blockage in a patient with mutant-Oncotarget · 2018
   Article
5. Characterization of gene mutations and copy number changes in acute myeloid leukemia using a rapid target enrichment protocol.Haematologica · 2015
   Article
6. The interplay of autophagy and β-Catenin signaling regulates differentiation in acute myeloid leukemia.Cell death discovery · 2015
   Article
7. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: are we closer to knowing who needs it?Current hematologic malignancy reports · 2014
   Review
8. Dasatinib accelerates valproic acid-induced acute myeloid leukemia cell death by regulation of differentiation capacity.PloS one · 2014
   Article
9. EGFR inhibitors exacerbate differentiation and cell cycle arrest induced by retinoic acid and vitamin D3 in acute myeloid leukemia cells.Cell cycle (Georgetown, Tex.) · 2013
   Article
10. MEK/ERK dependent activation of STAT1 mediates dasatinib-induced differentiation of acute myeloid leukemia.PloS one · 2013
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

10 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as